Research
Hormonal
GLP-1 receptor agonists have shown promising results in reducing liver enzymes and improving MASLD.
Practitioners may consider GLP-1 RAs as a therapeutic option for MASLD.
StrongSupportsmedium confidence
Recently, incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have shown promising results in reducing liver enzymes and improving MASLD.
Why this rating
The claim is supported by a comprehensive literature search.
Source
The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions
Maria Zasadzińska et al. · Journal of Diabetology · 2025
reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →